Drug Makers Face Higher Relabeling Burden For Antibacterial Resistance Info
Executive Summary
FDA plans to issue a yearly update on the susceptibility of bacteria to treatment by individual antibiotics and has drafted guidance that calls on drug makers to revise labeling for systemic antibacterial products accordingly